Navigation Links
Resverlogix Phase 1b/2a Study Meets Primary Endpoint
Date:8/25/2009

e including Drs. Nissen, Nicholls, Ballantyne, Taylor, and Kastelein for a Phase 2 study in cardiovascular disease patients which will be discussed in conjunction with the 2009 European Society of Cardiology Congress meeting in Barcelona, Spain. Resverlogix will be attending this important cardiovascular meeting and will communicate the results of the 28 day study to potential partners in greater detail, under confidentiality agreement. Furthermore, Dr. Norman Wong will present RVX-208 data on September 2, 2009 for Resverlogix during this meeting.

Since RVX-208 increases ApoA-I by production the Phase 1b/2a trial also examined early markers for ApoA-I production and reverse cholesterol transport such as pre-beta-HDL and Alpha1-HDL. Approximately half of the subjects had low levels of HDL cholesterol, a condition associated with significant increased risk of cardiovascular disease.

"Showing in the Phase 1b/2a trial that we met the primary endpoint of increasing plasma ApoA-I in a safe and tolerable way is a huge milestone for Resverlogix," stated Donald J. McCaffrey, President CEO of Resverlogix. "There is an enormous unmet medical need in treating atherosclerosis and cardiovascular disease and the ApoA-I increases achieved by RVX-208 may just do that. We expect to update shareholders with further details of these activities later this year," added McCaffrey.

In addition to successfully completing the Phase 1b/2a trial, Resverlogix has also completed two arms of a Phase 1 BE (bio-equivalency) study for RVX-208 with the final arm being scheduled for completion in the end of the third quarter. The Phase 1 BE trial is a program designed to show that the newly formed capsule version of RVX-208 is equivalent to the earlier powder in a bottle version that has been used in all trials to date.

In unrelated news Mr. Kelly McNeill, Resverlogix CFO, will be leaving his current position effective September 18, 2009 and returning to Winnipeg for
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
2. Resverlogix Provides Quarterly Update
3. Resverlogix Board of Directors Update
4. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
5. Resverlogix Announces Closing of Debt Redemption
6. Resverlogix Eliminates Sixty Percent of Remaining Debt
7. Resverlogix Issues a Management Statement
8. Resverlogix Board of Directors Update
9. Resverlogix Notice of Conference Call & Webcast
10. Jan Gray Joins Resverlogix Board of Directors
11. Resverlogixs Lead Drug Featured in Key Scientific Publication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 The ... encourage all types of inventions. They focus on learning ... noticing this community gravitate toward bringing their ideas to ... DIY Biology Movement, works on making projects using biology. ... DNA of plants to make them glow with bioluminescence ...
(Date:5/23/2013)... , May 23, 2013 Virobay, Inc. ... for pain has reached an important milestone, as Virobay ... VBY-036 - a selective cathepsin S inhibitor.   ... a double-blind, randomized, placebo-controlled study designed to evaluate the ... VBY-036 in healthy adults. "The initiation of ...
(Date:5/23/2013)... Md. , May 23, 2013 Northwest ... biotechnology company developing DCVax ® personalized immune therapies ... use its exhibit at this year,s American Society Of ... to highlight its leadership role in immune therapy.  ... The ASCO annual meeting is the pre-eminent conference focused ...
(Date:5/23/2013)... During the conduct of research involving ... principles of good clinical practice (GCP) and human ... Lim, Fellow, Clinical Development at Novartis Pharmaceuticals, will ... the International Conference on Harmonization (ICH) Guideline for ... the conduction of clinical trials ,     Apply ...
Breaking Biology Technology:Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Adhering to Good Clinical Practice, New Webinar Hosted by Xtalks 2
... NEW YORK, April 3 /PRNewswire-Asia-FirstCall/ -- China Agri-Business, ... agricultural,application products through its operating company in China, ... 31,2008. , Revenue for ... a,decrease of 3.8% as compared to $3,037,414 for ...
... CAMBRIDGE, Mass., April 3 Verenium Corporation (Nasdaq: ... development of high-performance specialty enzymes and next-generation cellulosic ... of Verenium,s demonstration-scale facility in Jennings, Louisiana, and ... with BP, Verenium is now consolidating its research ...
... tiny wires with a diameter as small as ... for devices of the future, both in technology like ... circuits for next generation of electronics. But in order ... must be precisely controlled, and researchers must better understand ...
Cached Biology Technology:China Agri-Business Announces 2008 Operating Results 2China Agri-Business Announces 2008 Operating Results 3China Agri-Business Announces 2008 Operating Results 4China Agri-Business Announces 2008 Operating Results 5Verenium Announces Organizational Changes 2Verenium Announces Organizational Changes 3Researchers peer into nanowires to measure dopant properties 2
(Date:5/23/2013)... HOUSTON (May 23, 2013) A new report ... responsible for helping pupils engage in at least 60 ... school day. , No more than half of American ... hour of vigorous or moderate intensity physical activity daily, ... , "Because children are in school for nearly half ...
(Date:5/23/2013)... Frontiers, one of the world,s largest and fastest ... new journal, Frontiers in Bioengineering and Biotechnology ... all specialties, Frontiers in Bioengineering and Biotechnology ... diverse and emerging bioengineering and biotechnology research to ... in Bioengineering and Biotechnology will provide an ...
(Date:5/22/2013)... Forest Service scientists are part of "Landscapes of Resilience", ... Foundation, will examine how collaborative planning and stewardship of ... , The TKF Foundation announced today that Landscapes of ... funding. In addition to research on the role of ... the 3-year, $585,000 grant will contribute to the creation ...
Breaking Biology News(10 mins):Schools should provide students with daily physical activity, IOM recommends 2Frontiers launches new open-access journal in Bioengineering and Biotechnology 2'Landscapes of Resilience' to study how people use nature as a source of recovery 2
... thousand species (give or take 1.3 million). That is ... the most precise calculation ever offered -- with 6.5 million ... of the total) dwelling in the ocean depths. Announced ... based on an innovative, validated analytical technique that dramatically narrows ...
... physics-based theory could give researchers a deeper understanding of ... polymers. This advance provides a better picture of how ... plastics and other polymeric materials. Kenneth S. Schweizer, ... science and engineering at the University of Illinois, and ...
... An extreme form of pregnancy-related nausea and vomiting known ... of women each year and can lead to hospitalization and ... the only victims. A joint study by ... children whose mothers suffered from HG while carrying them were ...
Cached Biology News:How many species on Earth? 8.7 million 2How many species on Earth? 8.7 million 3How many species on Earth? 8.7 million 4How many species on Earth? 8.7 million 5New theory may shed light on dynamics of large-polymer liquids 2Extreme morning sickness could lead to lifelong emotional, behavioral disorders in kids 2
... is a hairpin primer labeled with ... and non-fluorescent quencher) and a 3 ... is identical to the UniPrimer provided ... (S7901) and is provided at a ...
...
Mouse monoclonal antibody raised against a partial recombinant EBI3. NCBI Entrez Gene ID = EBI3...
... The JASCO Model AS-2055 and AS-2057 ... greater productivity and,the highest possible level of ... to 384 well positions (microplate) for,laboratory automation ... rack for 84 micro-vials or the standard ...
Biology Products: